Psoriasis treatment: current and emerging directed therapies

Area of Science:

• Dermatology and Immunology
• Pharmacology

Background:

• Psoriasis significantly impacts quality of life, with psoriatic arthritis affecting up to 40% of patients.
• Traditional therapies like methotrexate and ciclosporin have efficacy limitations due to side effect profiles.
• Increased understanding of psoriasis immunopathogenesis drives development of targeted treatments.

Purpose of the Study:

• To review newly approved and investigational biological agents for psoriasis treatment.
• To highlight agents targeting specific cells and molecules involved in psoriatic plaque development.
• To encourage reconsideration of systemic treatments for moderate to severe psoriasis.

Main Methods:

• Review of Phase II and III clinical trial data for emerging biological agents.
• Focus on recently approved agents: alefacept, efalizumab, and etanercept.
• Inclusion of data on agents in development: adalimumab and infliximab.

Main Results:

• New biological agents demonstrate targeted mechanisms for psoriasis management.
• Approved and investigational agents show promise for improved efficacy and tolerability.
• Patient surveys indicate a desire for more aggressive treatment strategies.

Conclusions:

• Emerging biological therapies represent a significant advancement in managing moderate to severe psoriasis.
• Targeted agents offer potential for fewer side effects, promoting wider adoption of systemic treatment.
• Enhanced collaboration between dermatologists and rheumatologists is crucial for optimal patient care, especially for psoriatic joint disease.